Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.73 |
| ▸ | PPARG | P37231 | 6/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.73 |
| ▸ | F7 | P08709 | 4/20 | 0.73 |
| ▸ | F3 | P13726 | 4/20 | 0.73 |
| ▸ | PPARD | Q03181 | 4/20 | 0.73 |
| ▸ | PPARA | Q07869 | 4/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.73 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | RXRA | P19793 | 2/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652290 | 1.00 | MAPT (0.81) | MAPTALDH1A1PPARGCYP19A1F7 | |
| SCHEMBL12961411 | 1.00 | MAPT (0.81) | MAPTALDH1A1PPARGCYP19A1F7 | |
| SCHEMBL652501 | 1.00 | MAPT (0.81) | MAPTALDH1A1PPARGCYP19A1F7 | |
| SCHEMBL29922202 | 0.94 | MAPT (0.81) | MAPTALDH1A1PPARGCYP19A1F7 | |
| SCHEMBL655399 | 0.94 | MAPT (0.81) | MAPTALDH1A1PPARGCYP19A1F7 | |
| SCHEMBL31570910 | 0.94 | MAPT (0.81) | MAPTALDH1A1PPARGCYP19A1F7 | |
| SCHEMBL15335274 | 0.94 | MAPT (0.81) | MAPTALDH1A1PPARGCYP19A1F7 | |
| SCHEMBL15956263 | 0.94 | MAPT (0.81) | MAPTALDH1A1PPARGCYP19A1F7 | |
| SCHEMBL3407185 | 0.91 | ALDH1A1 (0.71) | MAPTALDH1A1PPARGCYP19A1F7 | |
| SCHEMBL22451075 | 0.91 | ALDH1A1 (0.71) | MAPTALDH1A1PPARGCYP19A1F7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041696-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-12 | — | — | US | claimed |
| US-20250216407-A1 | LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS | INIPHARM, INC. | 2025-07-03 | — | — | US | claimed |
| WO-2024229108-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-07 | — | — | WO | claimed |
| WO-2023192314-A1 | LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS | INIPHARM, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260041696-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-12 | — | — | US | disclosed |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250216407-A1 | LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS | INIPHARM, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2024229108-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2023192314-A1 | LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS | INIPHARM, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | CHIBA UNIVERSITY (JP) | 2023-09-28 | — | — | US | disclosed |
| US-11723929-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | disclosed |
| EP-3377056-B1 | STABLE ANALOGS OF CYP450 LIPID METABOLITES AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2020-09-23 | — | — | EP | disclosed |
| US-10369141-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180200244-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180185309-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROPATHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180125803-A1 | METHODS OF INHIBITING PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-10 | — | — | US | disclosed |
| US-20120046251-A1 | INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO INHIBIT OR PREVENT NIACIN-INDUCED FLUSHING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-23 | — | — | US | disclosed |
| US-7951831-B2 | Use of inhibitors of soluble epoxide hydrolase to synergize activity of COX and 5-LOX inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-31 | — | — | US | disclosed |
| US-20060178347-A1 | Use of inhibitors of soluble epoxide hydrolase to synergize activity of COX and 5-LOX inhibitors | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | FABP7, ADH1B, ELOVL1 | MAPT 2470/4885ALDH1A1 266/4885PPARG 80/4885 |
| US-11723929-B2 | Methods of improving cell-based therapy | EPHX1, EPHX2, NCEH1 | MAPT 4272/4885ALDH1A1 182/4885PPARG 1194/4885 |
| US-20180200244-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | ELOVL1, ELOVL3, IL2 | MAPT 3484/4885ALDH1A1 386/4885PPARG 47/4885 |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | FABP7, ADH1B, ELOVL1 | MAPT 2470/4885ALDH1A1 266/4885PPARG 80/4885 |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | MAPT 2450/4885ALDH1A1 756/4885PPARG 11/4885 |
| US-20180125803-A1 | METHODS OF INHIBITING PAIN | ATP2A3, ATP2A1, ATP2A2 | MAPT 883/4885ALDH1A1 1449/4885PPARG 1225/4885 |
| US-20260041696-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | ALOX5, ALOX15, ALOX15B | MAPT 2662/4885ALDH1A1 2772/4885PPARG 202/4885 |
| US-20120046251-A1 | INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO INHIBIT OR PREVENT NIACIN-INDUCED FLUSHING | EPHX1, NCEH1, FAAH | MAPT 3209/4885ALDH1A1 439/4885PPARG 735/4885 |
| US-10369141-B2 | Methods of improving cell-based therapy | ELOVL1, ELOVL3, IL2 | MAPT 3484/4885ALDH1A1 386/4885PPARG 47/4885 |
| US-20180185309-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROPATHY | GLS, REN, SLC5A2 | MAPT 1956/4885ALDH1A1 2377/4885PPARG 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.